Navigation Links
FDA Grants Orphan Drug Status To Morphotek's Amatuximab (MORAb-009)
Date:11/12/2012

EXTON, Pa., Nov. 12, 2012 /PRNewswire/ -- Morphotek® Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational cancer drug, amatuximab (MORAb-009) for the treatment of malignant pleural mesothelioma, the most common form of mesothelioma, which accounts for around 2,500 cases a year in the United States. This disease affects the pleura, which is the thin balloon shaped lining of the lungs.1

The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the safe and effective treatment, diagnosis, or prevention of a rare disease/disorder that affects fewer than 200,000 people in the United States.2  Under the ODA, orphan designation qualifies the sponsor of the product for certain incentives, such as tax credits, prescription drug user fee waivers for the development product, and a seven year period of marketing exclusivity from the date of approval.

"We are very pleased to receive orphan drug designation for amatuximab for the potential treatment of malignant pleural mesothelioma," said Julia Maltzman, M.D., Senior Director of Clinical Development at Morphotek.  "We believe that addressing unmet medical needs, no matter the size of the patient population, is essential to the achievement of our human health care mission, which is to give first thought to patients and their families and to helping increase the benefits that health care provides.  Ultimately, this antibody has the potential to provide an additional treatment option for patients suffering from an extremely serious disease." 

Amatuximab (MORAb-009) is an investigational chimeric IgG1 antibody that targets a cell surface glycoprotein, mesothelin, which is over-expressed in a number of cancers. Mesothelin is thought to be involved in cell adhesion. Its presence
'/>"/>

SOURCE Morphotek Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... , NASHVILLE, Tenn., Oct. 27 Cumberland Pharmaceuticals Inc. ... report third quarter 2009 financial results before the market opens ... live Internet webcast will be held on Tuesday, November 10, ... , To participate on the call, please dial 888-417-8462 (for ...
... Denver ophthalmologist recently became the first in Colorado to implant ... bar for patient care in the state while increasing the ... director of Cutarelli Vision in Denver and Fort Collins, said ... eye of a 70-year-old man whose cataracts in his left ...
Cached Medicine Technology:Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009 2Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens 2Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens 3
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... The risk of burns from fires and cooking accidents ... extra cautious, an expert says. "Between Thanksgiving and ... patients coming in with burns," said Dr. Steven Sandoval, ... Center of Stony Brook University Hospital in New York. ... if not careful, could quickly turn tragic," Sandoval said ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... 25, 2014 Each year trauma accounts ... million hospital admissions across the nation (according to ... CDC’s National Hospital Ambulatory Medical Care Survey ... conducted in 2010. They estimated that there were between ... in a primary diagnosis of broken bone or fracture. ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... 9 Genomma Lab Internacional, S.A.B. de C.V. ... leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products ... initiate the operation of a stock repurchase fund according ... Directors for an amount of up to Ps. 100 ...
... Nash Corporation (Nasdaq: KNSY ) today announced ... second quarter ended December 31, 2008 at 7:30 A.M. ... Kaufmann, President and CEO, will be hosting a teleconference ... at 9:00 A.M. Eastern Time. To participate in ...
... for immunized seniors, study found, , , FRIDAY, Jan. 9 (HealthDay ... every year could cut your risk of dying from flu ... isn,t always a perfect match for the strains circulating in ... Medicine study that included 10 flu seasons, worth of ...
... but they could signal later trouble , , FRIDAY, Jan. ... to worry about whether their disease might slow their ... function are accelerated among those with the blood sugar ... issue of Neuropsychology , scientists from the University ...
... Jan. 9 The New Combituck(TM) procedure brings the ... tummy tuck, or abdominoplasty, has been the only option ... after weight fluctuations or child birth. A new procedure, ... abdominal skin and fat layer, without the weeks off ...
... the Centers for Medicare and Medicaid Services (CMS) released ... national coverage determination (NCD). This proposed legislation would allow ... patients with all types of cancer. The proposed decision ... addition to initial diagnosis. Two important items in the ...
Cached Medicine News:Health News:Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference 2Health News:You're Never Too Old for a Flu Shot 2Health News:You're Never Too Old for a Flu Shot 3Health News:Diabetes Linked to Cognitive Problems 2Health News:Doctors at Allure Medical Spa Are Getting the Results of a Tummy Tuck Without the Downtime 2Health News:SNM praises CMS decision to expand reimbursement for cancer treatment 2
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... CARDIAC M Myoglobin assay for use ... The Cardiac reader analyzer is a ... include: always ready to use (stand-by ... batch specific data entered automatically using ...
IRMA kit for detection of the cardiac marker Myoglobin...
... The CALBIOTECH INC. (CBI) Prolactin ELISA kit ... prolactin in human serum or plasma. Human ... polypeptide hormone with a molecular weight of ... based on a solid phase direct sandwich ...
Medicine Products: